0001628280-24-009083.txt : 20240305 0001628280-24-009083.hdr.sgml : 20240305 20240305175525 ACCESSION NUMBER: 0001628280-24-009083 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SACCARO JAMES CENTRAL INDEX KEY: 0001593636 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41528 FILM NUMBER: 24722858 MAIL ADDRESS: STREET 1: ONE BAXTER PARKWAY CITY: DEERFIELD STATE: IL ZIP: 60015 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GE HealthCare Technologies Inc. CENTRAL INDEX KEY: 0001932393 STANDARD INDUSTRIAL CLASSIFICATION: X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 882515116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 WEST MONROE STREET CITY: CHICAGO STATE: IL ZIP: 60661 BUSINESS PHONE: 833-735-1139 MAIL ADDRESS: STREET 1: 500 WEST MONROE STREET CITY: CHICAGO STATE: IL ZIP: 60661 FORMER COMPANY: FORMER CONFORMED NAME: GE Healthcare Holding LLC DATE OF NAME CHANGE: 20220603 4 1 wk-form4_1709679314.xml FORM 4 X0508 4 2024-03-01 0 0001932393 GE HealthCare Technologies Inc. GEHC 0001593636 SACCARO JAMES 500 W. MONROE STREET CHICAGO IL 60661 0 1 0 0 Chief Financial Officer 0 Common Stock, par value $0.01 per share 2024-03-01 4 A 0 10245 0 A 71938 D Employee Stock Option (right to buy) 92.72 2024-03-01 4 A 0 29141 0 A 2034-03-01 Common Stock, par value $0.01 per share 29141 29141 D Award of restricted stock units with respect to GE HealthCare Technologies Inc. ("GE HealthCare") common stock, of which 33% will vest on September 1, 2025, 33% will vest on September 1, 2026, and 34% will vest on September 1, 2027, subject to certain conditions. Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare common stock. Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 1, 2025, 33% will become exercisable on September 1, 2026, and 34% will become exercisable on September 1, 2027, subject to certain conditions. /s/ Frank R. Jimenez, General Counsel and Corporate Secretary, as attorney-in-fact 2024-03-05